Interim results from the phase 2 ENZA-p study (NCT04419402) show that adding 177Lu-PSMA-617 to enzalutamide...

Positive results from the TROPION-Breast01 phase 3 trial showed that a specifically engineered TROP2...

Shared decision-making is more than being attentive to patients’ needs or concerns – it also represents...

A multidisciplinary surgical approach implemented at the Mater Hospital, Dublin, has improved outcomes...

Welcome to the latest edition of Update Oncology and Haematology. Despite the ongoing pressure on healthcare...

Cervical cancer is predominantly a disease of younger women, with over 58 per cent of patients...

Targeted therapies in metastatic prostate cancer and the implications of the Triton3 trial. Prostate...

First described in 1848, multiple myeloma (MM), also known as plasma cell myeloma, is characterised by...

The National Cancer Control Programme recently published an updated version of the Nationa...

Testicular cancer is the most common cancer in men aged 15-to-45 years and represents one of...

Our understanding of lung cancer and how to manage it is evolving with unprecedented speed and...

The use of a novel agent, sacituzumab govitecan, an antibody-drug conjugate, resulted...